Back on January 23, 2021, TrialSite reported that the Montreal Heart Institute’s COLCOONA trial’s results showed promise. The study involving 4,488 COVID-19 patients was associated with…
On Sunday January 24th, Greece approved colchicine, an inexpensive medicine for gout, among other things, to be included in the protocol of oral treatments for…
TrialSite News has followed the COLCORONA trial with interest, reporting recently that the findings were looking promising. Now the sponsor, the Montreal Heart Institute (MHI),…
TrialSite recently reported that the independent data monitoring committee recommended to continue the Montreal Heart Institute study investigating the use of gout medication colchicine to help…
Back in June, TrialSite introduced the COLCORONA study led by the Montreal Heart Institute—a Phase 3 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety…
UT Southwestern Medical Center researchers are investigating existing, available drugs that could potentially help treat mild to moderate COVID-19 cases. This move by the number…
There is presently no available, FDA-approved medicine that can be administered at a patient’s home that can prevent the negative progression of SARS-CoV-2 symptoms leading…
The Montreal Heart Institute recently announced that the independent data monitoring committee (DMC) of a clinical trial, after completing a futility analysis, recommended it continue…
A clinical investigator from the VA New York Harbor Healthcare System in New York, NY, recently presented results of the COLCHICINE-PCI trial to the American…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
